• AMBER: A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combination regimen versus a regimen consisting of darunavir/cobicistat fixed dose combination coadministered with emtricitabine/tenofovir disoproxil fumarate fixed dose combination in antiretroviral treatment-naïve human immunodeficiency virus type 1 infected subjects. (TMC114FD2HTX3001)
• BESTT Women's Study: Bone Evaluation in HIV-positive women who switch from Truvada/NNRTI to Triumeq
• Community interventions to prevent violence against women and girls in informal settlements in Mumbai: the SNEHA-TARA pragmatic cluster randomised controlled trial
• The Bangladesh D:CLARE Project [Diabetes: Community-Led Awareness, Response and Evaluation]
• DISCOVER: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection (GS-US-412-2055)
• EMERALD: a randomized, active-controlled, open-label study to evaluate the efficacy and safety of switching to a D/C/F/TAF once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with FTC/TDF
• FLAIR: A Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
• GS-US-292-1823: A Phase 3b, Randomised, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of ABC/3TC plus a Third Antiretroviral Agent to the E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects
• GS-US-292-1826: A Phase 3b, Randomised, Open-Label Study to Evaluate Switching from a TDF Containing Regimen to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 Years
• GS-US-380-1489: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
• GS-US-380-1490: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
• HALT-LTBI study
• HIPvac: Randomised controlled trial of Imiquimod cream vs. podophyllotoxin in combination with quadrivalent HPV or control vaccination in the treatment and prevention of recurrence of anogenital warts
• JIAH – Jharkhand Initiative for Adolescent Health (Community Youth Teams facilitating participatory adolescent groups, youth leadership training and livelihood promotion to improve school enrolment, nutrition and mental health among adolescent girls in rural eastern India: a cluster randomised controlled trial)
• MAVMET: A multicentre, 48 week randomised controlled factorial trial of adding maraviroc and/or metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapy
• PrEP IMPACT Trial: A pragmatic health technology assessment of PrEP and implementation
• Safetxt: A randomised controlled trial of an intervention delivered by mobile phone messaging to reduce sexually transmitted infections (STI) by increasing sexual health precaution behaviours in young people
• SEQUENCE digital - Sexual health equity through evidence-based online clinical care (Improving sexual health for all, in a digital NHS)
• STOP HCV-1: Stratified Treatment OPtimisation for HCV-1: An open-label randomised controlled trial (RCT) testing biomarker-stratified short-course first-line and re-treatment direct-acting antiviral (DAA) oral treatment regimens to cure mild chronic Hepatitis C (HCV) disease
• SUPA: Supporting Uptake and adherence to antiretrovirals
• TANGO: A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressed
• VITA: A randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis